Avid Bioservices Inc (CDMO)

[biopharm]

The more I keep looking over this Conference on Notch Targeting in Cancer and Peregrine KOL Dmitry Gabrilovich presenting, the more I see this will directly reinforce the MOA of Bavituximab and show the astronomical value that PS targeting presents in cancer and vaccines.

Notch signalling: a simple pathway
becomes complex

Sarah J. Bray

Abstract |

A small number of signalling pathways are used iteratively to regulate cell fates, cell proliferation and cell death in development. Notch is the receptor in one such pathway, and is unusual in that most of its ligands are also trans membrane proteins; therefore signalling is restricted to neighboring cells. Although the intracellular transduction of the Notch signal is remarkably simple, with no secondary messengers, this
pathway functions in an enormous diversity of developmental processes and its dysfunction is implicated in many cancers.

http://mcdb.colorado.edu/labs1/xue/MCDB4426/pdf%20files/Notch%20review%202.pdf

This is one part of Notch Signaling I've read in a few publications but posting this one-- in that the signaling is between adjacent or neighboring cells which makes sense. A tumor grows and can metastasize to another non-adjacent organ/part of the body.

This publication is from 2006 and does not mention Phosphatidylserine or flipped-PS.... because it was not understood at the time and I can guarantee that Dr. Dmitry Gabrilovich, at the Notch Signaling (but notice how its called Notch Targeting?) ... will make big mention of Phosphatidylserine.

I think that is another big part of calling it "Notch Targeting" .... target flipped-PS (which is part of Notch) and magic happens.

Time will tell....